Taltz plus Zepbound superior to Taltz alone in psoriatic arthritis alongside obesity

Treatment with ixekizumab plus tirzepatide achieves greater disease control, physical function and weight loss vs. monotherapy in patients with psoriatic arthritis and obesity, according to data published in Arthritis & Rheumatology. “Overweight or obesity is disproportionately prevalent in PsA compared with the general population, with estimates ranging from 72% to 82%,” Joseph F. Merola,